Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Diffuse Large B-Cell Lymphoma Excellence Forum

Diffuse Large B-Cell Lymphoma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Michael R Green, PhD, The University of Texas MD Anderson Cancer Center, Houston, Texas
Conference Coverage
Emerging Role of Epigenetic Therapies in Follicular Lymphoma and DLBCL Treatment
02/15/2024

Featuring Michael R Green, PhD

Featuring Michael R Green, PhD ...
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Michael Green, PhD, discusses the role of epigenetic therapies in treating lymphoma.
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Michael Green, PhD, discusses the role of epigenetic therapies in treating lymphoma.
At the 2023 Lymphoma, Leukemia &...
02/15/2024
Lymphoma, Leukemia & Myeloma Network
Alan Cooper, BS, University of Chicago
Videos
Next Steps for Validating CD5 IHC Positive DLBCL Types Benefiting From Targeted Therapies
02/15/2024

Featuring Alan Cooper, BS

Featuring Alan Cooper, BS
Alan Cooper, lead study author, discussed follow-up research steps that would seek to validate CD5 immunohistochemistry positive diffuse large B-cell lymphoma types that could benefit from specific targeted therapies.
Alan Cooper, lead study author, discussed follow-up research steps that would seek to validate CD5 immunohistochemistry positive diffuse large B-cell lymphoma types that could benefit from specific targeted therapies.
Alan Cooper, lead study author,...
02/15/2024
Oncology
Justin Kline, MD
Videos
Novel CD5 Biomarker Effective for Identifying DLBCL Subtypes Sensitive to BTK Inhibitor Therapy
02/08/2024

Featuring Justin Kline, MD

Featuring Justin Kline, MD
Justin Kline, MD, discussed CD5 gene expression signature as a useful biomarker to identify diffuse large B-cell lymphoma subtypes vulnerable to BTK inhibitor therapies.
Justin Kline, MD, discussed CD5 gene expression signature as a useful biomarker to identify diffuse large B-cell lymphoma subtypes vulnerable to BTK inhibitor therapies.
Justin Kline, MD, discussed CD5...
02/08/2024
Oncology
Oluwatobi Odetola, MD,
Conference Coverage
Promising Efficacy of Frontline Nivolumab in Combination With R-CHOP for Patients With High-Risk DLBCL
12/12/2023

Featuring Oluwatobi Odetola, MD

Featuring Oluwatobi Odetola, MD ...
During the 2023 ASH Annual Meeting in San Diego, Oluwatobi Odetola, MD, shared data from a phase 1b study that evaluated the safety and efficacy of nivolumab in combination with R-CHOP in high-risk DLBCL.
During the 2023 ASH Annual Meeting in San Diego, Oluwatobi Odetola, MD, shared data from a phase 1b study that evaluated the safety and efficacy of nivolumab in combination with R-CHOP in high-risk DLBCL.
During the 2023 ASH Annual...
12/12/2023
Oncology
Martin Hutchings, MD, PhD, Rigshospitalet, Copenhagen
Videos
Glofitamab Plus Polatuzumab Vedotin Shows Frequent, Durable Responses and Manageable Safety Among Patients With R/R DLBCL
12/12/2023

Featuring Martin Hutchings, MD, PhD

Featuring Martin Hutchings, MD, PhD ...
At the 65th ASH Annual Meeting, Martin Hutchings, MD, discussed updated data on the combination of glofitamab plus polatuzumab vedotin, which yielded high response rates and manageable safety among heavily pretreated patients with diffuse...
At the 65th ASH Annual Meeting, Martin Hutchings, MD, discussed updated data on the combination of glofitamab plus polatuzumab vedotin, which yielded high response rates and manageable safety among heavily pretreated patients with diffuse...
At the 65th ASH Annual Meeting,...
12/12/2023
Oncology
Narendranath Epperla, MD, MS
Conference Coverage
Analyzing Outcomes of Tafasitamab for the Treatment of R/R DLBCL Among Racial and Ethnic Minorities
12/11/2023

Featuring Narendranath Epperla, MD, MS

Featuring Narendranath Epperla, MD, M...
At the 2023 ASH Annual Meeting, Narendranath Epperla, MD, MS, presented a retrospective cohort study analyzing the patterns and outcomes of treatment with tafasitamab among patients with R/R diffuse large B-cell lymphoma across racial and...
At the 2023 ASH Annual Meeting, Narendranath Epperla, MD, MS, presented a retrospective cohort study analyzing the patterns and outcomes of treatment with tafasitamab among patients with R/R diffuse large B-cell lymphoma across racial and...
At the 2023 ASH Annual Meeting,...
12/11/2023
Oncology
Charalambos Andreadis, MD 
Conference Coverage
Ibrutinib With Standard Conditioning and as Consolidation Therapy Following AutoHCT Well-Tolerated Among Patients With DLBCL
12/10/2023

Featuring Charalambos Andreadis, MD 

Featuring Charalambos Andreadis, MD  ...
At the 65th ASH Annual Meeting, Charalambos Andreadis, MD, presented on a phase 3 trial evaluating the efficacy of the addition of ibrutinib to autoHCT as conditioning and as consolidation therapy for patients with R/R ABC diffuse large...
At the 65th ASH Annual Meeting, Charalambos Andreadis, MD, presented on a phase 3 trial evaluating the efficacy of the addition of ibrutinib to autoHCT as conditioning and as consolidation therapy for patients with R/R ABC diffuse large...
At the 65th ASH Annual Meeting,...
12/10/2023
Oncology
Tycel Phillips, MD
Videos
FDA Approval of Epcoritamab for Patients With R/R Diffuse Large B-Cell Lymphoma
07/06/2023

Featuring Tycel Phillips, MD

Featuring Tycel Phillips, MD
Tycel Phillips, MD, shares insights into the recent FDA approval of epcoritamab as a treatment for patients with relapsed/refractory DLBCL not otherwise specified, including indolent lymphoma and high-grade B-cell lymphoma.
Tycel Phillips, MD, shares insights into the recent FDA approval of epcoritamab as a treatment for patients with relapsed/refractory DLBCL not otherwise specified, including indolent lymphoma and high-grade B-cell lymphoma.
Tycel Phillips, MD, shares...
07/06/2023
Oncology
Lorenzo Falchi, MD
Videos
Frontline Treatment With Epcoritamab Plus R-CHOP for Patients With High-Risk DLBCL
06/19/2023
Lorenzo Falchi, MD presents updated EPCORE NHL-2 data on epcoritamab combined with R-CHOP for the treatment of patients with high-risk diffuse large B-cell lymphoma.
Lorenzo Falchi, MD presents updated EPCORE NHL-2 data on epcoritamab combined with R-CHOP for the treatment of patients with high-risk diffuse large B-cell lymphoma.
Lorenzo Falchi, MD presents...
06/19/2023
Oncology
Lorenzo Falchi, MD
Videos
Glofitamab Monotherapy for Patients With R/R Diffuse Large B-Cell Lymphoma
06/13/2023
Lorenzo Falchi, MD presents extended follow-up from a pivotal phase 2 study on CD20-CD3 bispecific antibody glofitamab monotherapy for patients with R/R DLBCL.
Lorenzo Falchi, MD presents extended follow-up from a pivotal phase 2 study on CD20-CD3 bispecific antibody glofitamab monotherapy for patients with R/R DLBCL.
Lorenzo Falchi, MD presents...
06/13/2023
Oncology

Advertisement

Recent Stories

Jeremy Abramson, MD
Conference Coverage
Glofitamab Plus Gemcitabine and Oxaliplatin Demonstrates Benefit for Patients With R/R Diffuse Large B-Cell Lymphoma
06/27/2024
Jeremy Abramson, MD, shares data from the 2024 EHA Congress from the STARGLO trial on the survival benefit demonstrated by glofitamab plus gemcitabine and oxaliplatin (GemOx) therapy vs rituximab plus GemOx for patients with R/R DLBCL.
Jeremy Abramson, MD, shares data from the 2024 EHA Congress from the STARGLO trial on the survival benefit demonstrated by glofitamab plus gemcitabine and oxaliplatin (GemOx) therapy vs rituximab plus GemOx for patients with R/R DLBCL.
Jeremy Abramson, MD, shares data...
06/27/2024
Oncology
Matthew Matasar, MD
Conference Coverage
Odronextamab Demonstrates Efficacy, Safety for Heavily Pretreated Patients With DLBCL Progressing After CAR T-Cell Therapy
06/26/2024
Matthew Matasar, MD, shares data from the 2024 EHA Congress on the ELM-1 study, in which odronextamab monotherapy demonstrated efficacy and safety among pretreated patients with DLBCL who progressed after CAR T-cell therapy.
Matthew Matasar, MD, shares data from the 2024 EHA Congress on the ELM-1 study, in which odronextamab monotherapy demonstrated efficacy and safety among pretreated patients with DLBCL who progressed after CAR T-cell therapy.
Matthew Matasar, MD, shares data...
06/26/2024
Oncology
Matthew Matasar, MD
Conference Coverage
Evaluating the Efficacy of Odronextamab Plus CHOP vs R-CHOP Among Patients With Previously Untreated DLBCL
06/11/2024

Featuring Matthew Matasar, MD

Featuring Matthew Matasar, MD
Matthew Matasar, MD, discusses ongoing data from the phase 3 OLYMPIA-3 trial which examines odronextamab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) versus rituximab plus CHOP among patients with previously...
Matthew Matasar, MD, discusses ongoing data from the phase 3 OLYMPIA-3 trial which examines odronextamab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) versus rituximab plus CHOP among patients with previously...
Matthew Matasar, MD, discusses...
06/11/2024
Oncology
David Andorsky, MD, Rocky Mountain Cancer Centers
Videos
Significance of Patient Enrollment in Lymphoma Clinical Trials, Particularly Among Older Patients
06/04/2024

Featuring David Andorsky, MD

Featuring David Andorsky, MD
David Andorsky, MD, shares expert insight on the significance of clinical trials in lymphoma research, focusing on the inclusion of older patients in these studies.
David Andorsky, MD, shares expert insight on the significance of clinical trials in lymphoma research, focusing on the inclusion of older patients in these studies.
David Andorsky, MD, shares...
06/04/2024
Oncology
Sam Yamshon, MD, Weill Cornell Medicine
Conference Coverage
Safety of CAR T-Cell Therapy Following FDA Warning on Risk of Secondary Malignancies Following Treatment
05/06/2024

Featuring Sam Yamshon, MD

Featuring Sam Yamshon, MD
Sam Yamshon, MD, discusses the safety of CAR T-cell therapy following the FDA’s warning in late 2023 regarding the risk of patients developing secondary T-cell malignancies following this treatment.
Sam Yamshon, MD, discusses the safety of CAR T-cell therapy following the FDA’s warning in late 2023 regarding the risk of patients developing secondary T-cell malignancies following this treatment.
Sam Yamshon, MD, discusses the...
05/06/2024
Oncology

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement